
# SHORTER RR-TB REGIMEN (BPAL-L) IN PATIENTS ≥ 15 YRS

Based on Clinical Management of Rifampicin-Resistant Tuberculosis: Updated Clinical Reference Guide, September 2023 and Circular 2/23: Implementation of BPaL-L regimen, South African National Department of Health



≥ 30 kg: 200 mg daily

evidence for a risk of TdP when taken as

recommended

200 mg tab

3TC = lamivudine; ABC = abacavir; ALT = alanine aminotransferase; ART = antiretroviral therapy; AZT = zidovudine; CM = cryptococcal meningitis; DR-TB = drug-resistant tuberculosis; DST = drug sensitivity testing; DTG = dolutegravir; ECG = electrocardiogram; EDST = extended drug sensitivity testing; EFV = efavirenz; EPTB = extrapulmonary tuberculosis; EtO = ethionamide; FBC = full blood count; FLQs = fluoroquinolones; Hb = haemoglobin; HIV = human immunodeficiency virus; INJ = injectable; K<sup>+</sup> = potassium; Mg<sup>2+</sup> = magnesium; MGIT = Mycobacteria growth indicator tube; MTB = Mycobacterium tuberculosis; NCAC = National Clinical Advisory Committee; NVP = nevirapine; TB-NAAT = TB nucleic acid amplification test; PCAC = Provincial Clinical Advisory Committee; PI = protease-inhibitor; QTc = corrected QT interval; RR-TB = rifampicin-resistant tuberculosis; TDF = tenofovir; TdP = Torsades de Pointes; TEE = tenofovir+emtricitabine+efavirenz; TLD = tenofovir+lamivudine+dolutegravir; VL = viral load; XDR = extensively drug resistant

# **NEED HELP?**

ontact the TOLL-FREE National HIV & TB Health Care Worker Hotline 0800 212 506 / 021 406 6782

"WhatsApp" or send an SMS or "Please Call Me" to 071 840 157?

# **INCLUSION CRITERIA**

- Individuals with RR-TB: resistance based on initial genotypic result, while awaiting further susceptibility results. This includes prior exposure to BDQ, Pa or LZD for longer than 1 month, but resistance to BDQ and LZD must be excluded
- Non-severe extra-pulmonary RR-TB, including lymphadenopathy or pleural effusion
- Extensive pulmonary disease (i.e. bilateral, cavitary disease with significant fibrosis, scarring or cavities in 3 or more lung zones)—TB treatment should be extended to 9 months
- Patients who received <28 days of another regimen who are eligible for BPaL-L may switch to it. The

## **EXCLUSION CRITERIA**

- Documented resistance to bedaquiline or linezolid
- RR-TB with additional resistance to pretomanid or delamanid
- XDR-TB (resistance to the fluoroquinolones and bedaquiline or linezolid)
- Severe extra-pulmonary RR-TB meningitis, pericarditis, osteoarticular, abdominal or disseminated/ miliary disease
- Children under the age of 15 years (pretomanid safety not yet confirmed in this population)
- Pregnant women (pretomanid safety not yet confirmed in this population, replace Pa with DLM)

### HIV AND RR-TB CO-INFECTION All people co-infected with RR-TB and HIV should receive ART

- Important drug interactions
- EFV is contraindicated with BDQ and Pa
  Co-trimovazole can be given regardless of CD4 count a
- Co-trimoxazole can be given regardless of CD4 count and can be given with LZD: monitor FBC and neutrophils
- AZT and LZD should not be used together as both drugs can cause bone marrow suppression and thrombocytopenia

### ART-naïve patients

- In ART-naïve patients, initiate ART within 2 to 8 weeks of starting RR-TB treatment. Patients with CD4 < 50: initiate ART within 2 weeks. If RR-TB meningitis, initiate ART after 4-6 weeks to decrease the risk of IRIS. If RR-TB patient with CM: see ART guidelines
- Initiate TLD as first-line ART if patient weight ≥ 30 kg, provided adequate renal function. Use ABC if TDF contraindicated. If DTG 50 mg not available, contact the hotline to discuss

#### Re-starting ART

- Re-initiate on TLD if appropriate
- Provide adherence support and do VL after 3 months

Modifications in patients on ART when RR-TB treatment is initiated

- Patients on the following regimens qualify for a same day switch to TLD regardless of VL:
  - Any EFV or NVP-based regimens
  - AZT/3TC/DTG
  - Any PI-based regimen for < 2 years
- Patients with VL < 1000 on a PI-based regimen may also switch</li>
   to TLD with adherence support and a repeat VII after 2 menths
- to TLD with adherence support and a repeat VL after 3 months • Patients with 2 VLs  $\geq$  1000 two or more years after starting a
- PI regimen and confirmed adherence < 80% can switch to TLD • Patients with 2 VLs  $\ge$  1000 two or more years after starting a
- PI regimen and confirmed adherence > 80% should remain on the PI with consideration for a resistance test

Consult the 2023 ART Clinical Guidelines for more detailed information